Folistatin, insulin resistance and body composition in Colombian adults
PDF (Español (España))
HTML (Español (España))


insulin resistance

How to Cite

Toloza, F. J., Ricardo-Silgado, M. L., Mantilla-Rivas, J. O., Morales-Álvarez, M. C., Pérez-Matos, M. C., Pinzón-Cortés, J. A., Pérez-Mayorga, M., & Mendivil, C. O. (2018). Folistatin, insulin resistance and body composition in Colombian adults. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 5(1), 7–14.


Introduction: Follistatin is a protein with the ability to neutralize several hormones of the TGF-beta family including activin, bone morphogenetic proteins and myostatin. By inactivating activin, follistatin reduces FSH secretion. Besides ovary, follistatin is produced in several other tissues, hence it may have many other effects. In mice, genetic follistatin defficiency leads to insulin resistance (IR). However, the association between plasma follistatin and directly measured IR has not been evaluated in humans.
Methods: We determined in 81 participants aged 30 to 69 (56% women, 54% overweight, 13% obese) anthropometry, body composition, cardiovascular risk factors and multiple IR indices: Incremental area under the insulin curve, Gutt´s Insulin sensitivity index, homeostatic model assessment – insulin resistance (HOMA-IR) and fasting insulin. A subgroup of 21 participants additionally underwent a hyperinsulinemic/euglycemic clamp. Follistatin and myostatin were measured in fasting plasma using immunometric techniques.
Results: Mean plasma follistatin was 2.517±830 pg/mL, without differences by sex (p=0,55). Follistatin showed a trend towards a positive correlation with the percent lean mass (r=0,19, p=0,088) and towards a negative correlation with percent body fat (r= -0,19, p=0,097). Follistatin was not correlated with OGTT-derived IR indices but it did correlate with whole body insulinstimulated glucose uptake in the clamp (r=0,42, p=0,031). No correlation existed between plasma follistatin and myostatin.
Conclusion: Plasma follistatin showed a trend to a positive correlation with muscle mass, and negative with fat mass. This fits the known role of follistatin as an antagonist to myostatin. Even though follistatin was not associated with indirect IR indices, it was positively associated with directly measured insulin sensitivity in the clamp.
PDF (Español (España))
HTML (Español (España))


1. Hansen JS, Plomgaard P. Circulating follistatin in relation to energy metabolism. Mol Cell Endocrinol. 2016;433:87-93.
2. Hansen J, Rinnov A, Krogh-Madsen R, Fischer CP, Andreasen AS, Berg RM, Møller K, Pedersen BK, Plomgaard P. Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. Diabetes Metab Res Rev. 2013;29:463-72.
3. Ueno N, Ling N, Ying SY, Esch F, Shimasaki S, Guillemin R. Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci USA. 1987;84:8282-6.
4. Esch FS, Shimasaki S, Mercado M, Cooksey K, Ling N, Ying S, Ueno N, Guillemin R. Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol. 1987;1:849-55.
5. Takamura K, Tsuchida K, Miyake H, Tashiro S, Sugino H. Possible endocrine control by follistatin 315 during liver regeneration based on changes in the activin receptor after a partial hepatectomy in rats. Hepatogastroenterology. 2005;52:60-6.
6. Bondestam J, Horelli-Kuitunen N, Hildén K, Ritvos O, Aaltonen J. Assignment of ACVR2 and ACVR2B the human activin receptor type II and IIB genes to chromosome bands 2q22.2-->q23.3 and 3p22 and the human follistatin gene (FST) to chromosome 5q11.2 by FISH. Cytogenet Cell Genet. 1999;87:219-20.
7. Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvönen M. Structural basis for the inhibition of activin signalling by follistatin. EMBO J. 2006;25:1035-45.
8. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel K.
Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol. 2004;270:19-30.
9. Pentek J, Parker L, Wu A, Arora K. Follistatin preferentially antagonizes activin rather than BMP signaling in Drosophila. Genesis. 2009;47:261-73.
10. Shimasaki S, Koga M, Esch F, Cooksey K, Mercado M, Koba A, Ueno N, Ying SY, Ling N, Guillemin R. Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA. 1988;85:4218-22.
11. Lerch TF, Shimasaki S, Woodruff TK, Jardetzky TS. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions. J Biol Chem. 2007;282:15930-9.
12. Schneyer AL, Wang Q, Sidis Y, Sluss PM. Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab. 2004;89:5067-75.
13. Vamvini MT, Aronis KN, Chamberland JP, Mantzoros CS. Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males. J Clin Endocrinol Metab. 2011;96:3416-23.
14. Hansen J, Brandt C, Nielsen AR, Hojman P, Whitham M, Febbraio MA, Pedersen BK, Plomgaard P. Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine. Endocrinology. 2011;152:164-71.
15. Kerschan-Schindl K, Thalmann MM, Weiss E, Tsironi M, Föger-Samwald U, Meinhart J, Skenderi K, Pietschmann P. Changes in Serum Levels of Myokines and Wnt-Antagonists after an Ultramarathon Race. PLoS One. 2015;10:e0132478.
16. Hansen JS, Rutti S, Arous C, Clemmesen JO, Secher NH, Drescher A, Gonelle- Gispert C, Halban PA, Pedersen BK, Weigert C, Bouzakri K, Plomgaard P. Circulating Follistatin Is Liver-Derived and Regulated by the Glucagon-to-Insulin Ratio. J Clin Endocrinol Metab. 2016;101:550-60.
17. Hansen JS, Pedersen BK, Xu G, Lehmann R, Weigert C, Plomgaard P. Exercise- Induced Secretion of FGF21 and Follistatin Are Blocked by Pancreatic Clamp and Impaired in Type 2 Diabetes. J Clin Endocrinol Metab. 2016;101:2816- 25.
18. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23
19. Mendivil CO, Robles-Osorio L, Horton ES, Hamdy O, Caballero AE. Young Hispanics at risk of type 2 diabetes display endothelial activation, subclinical inflammation and alterations of coagulation and fibrinolysis. Diabetol Metab Syndr 2013;5:37.
20. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB. Validation of the insulin sensitivity index (ISI0,120): comparison with other measures. Diabetes Res Clin Pract 2000;47:177–184.
21. Matthews JNS, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. Br Med J 1990;27:230-235.
22. Zimmers TA, Davies MV, Koniaris LG, Haynes P, Esquela AF, Tomkinson KN, McPherron AC, Wolfman NM, Lee SJ. Induction of cachexia in mice by systemically administered myostatin. Science. 2002;296:1486-8.
23. Amthor H, Christ B, Rashid-Doubell F, Kemp CF, Lang E, Patel K. Follistatin regulates bone morphogenetic protein-7 (BMP-7) activity to stimulate embryonic muscle growth. Dev Biol. 2002;243:115-27.
24. Hill JJ, Davies MV, Pearson AA, Wang JH, Hewick RM, Wolfman NM, Qiu Y. The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem. 2002;277:40735-41.
25. Hill JJ, Qiu Y, Hewick RM, Wolfman NM. Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains. Mol Endocrinol. 2003;17:1144-54.
26. Näf S, Escote X, Ballesteros M, Yañez RE, Simón-Muela I, Gil P, Albaiges G, Vendrell J, Megia A. Serum activin A and follistatin levels in gestational diabetes and the association of the Activin A-Follistatin system with anthropometric parameters in offspring. PLoS One. 2014;9:e92175.
27. Teede H, Ng S, Hedger M, Moran L. Follistatin and activins in polycystic ovary syndrome: relationship to metabolic and hormonal markers. Metabolism. 2013;62:1394-400.
28. Wu H, Wu M, Chen Y, Allan CA, Phillips DJ, Hedger MP. Correlation between blood activin levels and clinical parameters of type 2 diabetes. Exp Diabetes Res. 2012;2012:410579.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.